Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-01 Single Ascending Dose Study in Healthy Participants
NCT07865442Phase 1Not yet recruiting
- Sponsor
- Altis Medicines
- Start
- Oct 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALT-01 in autoimmune disease (7 arms), sponsored by Altis Medicines. Primary endpoint: Treatment-Emergent Adverse Events at 169 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ALT-01
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT07865442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07865442.